Cargando…

Engineered antibodies: new possibilities for brain PET?

Almost 50 million people worldwide are affected by Alzheimer’s disease (AD), the most common neurodegenerative disorder. Development of disease-modifying therapies would benefit from reliable, non-invasive positron emission tomography (PET) biomarkers for early diagnosis, monitoring of disease progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehlin, Dag, Syvänen, Stina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879437/
https://www.ncbi.nlm.nih.gov/pubmed/31342134
http://dx.doi.org/10.1007/s00259-019-04426-0